Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

IRVINE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it has completed the sale of an additional 300,000 shares of its common stock, pursuant to the exercise in full of the over-allotment option granted to the underwriters in connection with Inari's recently completed underwritten public offering of 2,000,000 shares of common stock, at the public offering price of $81.00 per share, less underwriting discounts and commissions. After giving effect to the sale of these additional shares, a total of 2,300,000 shares of common stock were sold in the offering, for aggregate gross proceeds of approximately $186.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Inari.

Inari Medical Announces Closing of Underwriters' Over-Allotment Option in Connection with Offering of Common Stock

IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions. In addition, Inari has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are to be sold by Inari. The offering is expected to close on or about March 15, 2022, subject to customary closing conditions.

Inari Medical Announces Pricing of Offering of Common Stock

IRVINE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock. Inari also expects to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Inari.

Inari Medical Announces Proposed Offering of Common Stock

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve as a member of the Audit Committee of the board.

Inari Medical Appoints Robert Warner to Board of Directors

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q4 2021 Results - Earnings Call Transcript

IRVINE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2021.

Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Fourth Quarter and Full-Year 2021 Financial Results

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues

Inari Medical Inc (NASDAQ: NARI) expects Q4 FY21 sales of $82.8 million - $83.3 million, up 14% sequentially and 71% year-over-year (at the midpoint of the range), beating the consensus of $73.16 million. For FY21, the company sees revenue of $276.6 million - $277.1 million, up approximately 98% Y/Y, well ahead of the consensus of $267.12 million and prior guidance of $266 million - $268 million.

Inari Medical Reports Solid Preliminary Q4, FY21 Sales

IRVINE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue.

Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue

IRVINE, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time.

Inari Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

Marathon Digital Holdings

Block

Huge gains could be up ahead if the rest of the market sees these stocks in the same light as investment bank analysts.

3 High-Growth Stocks Wall Street Thinks Could Rise 50% or More

Moderna

Novavax

Our Foolish roundtable has three stocks to invest in as we enter our third year of the COVID pandemic.

3 COVID-19 Stocks That Should Beat the Market in 2022

CareDx

Nevro

It doesn't take a lot to own a piece of these rapidly growing healthcare businesses.

3 Unstoppable Growth Stocks You Can Buy for Less Than $100 Right Now

Inari Medical, Inc.'s (NARI) CEO Bill Hoffman on Q3 2021 Results - Earnings Call Transcript

Inari Medical (NASDAQ:NARI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Recap: Inari Medical Q3 Earnings

IRVINE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2021.

Inari Medical Reports Third Quarter 2021 Financial Results

IRVINE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive acute and long-term interim results from the first 500 pulmonary embolism (“PE”) patients enrolled in the FlowTriever Outcomes Registry (“FLASH”). At 48 hours post procedure, the major adverse event rate and mortality rate were low, at 1.4% and 0.2%, respectively. None of the deaths or major adverse events were device related. Collectively, these PE patients experienced substantial on-table improvements in hemodynamics and symptoms, which translated to 6-month improvements in cardiac function, functional status, and quality of life measures. The outcomes were achieved while limiting utilization of hospital resources, with less than 4% of patients receiving adjunctive therapy and a median of 0 days in the ICU post procedure.

Inari Medical Announces 6-month FLASH Registry Interim Data Demonstrating Benefits of Lytic-Free Mechanical Thrombectomy in 500 Real-World PE Patients

IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its third quarter financial results on Tuesday, November 9, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Third Quarter 2021 Financial Results

Centene

iShares Global Healthcare ETF

Vertex Pharmaceuticals

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.

Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund

IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism (“PE”) treated with the FlowTriever System versus catheter-directed thrombolysis (CDT). The trial design was presented at the 7th Annual Pulmonary Embolism Symposium, sponsored by the PERT Consortium®.

Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System in Pulmonary Embolism Patients

William Hoffman, President And CEO at Inari Medical (NASDAQ:NARI), made a large insider sell on October 7, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Hoffman sold 29,900 shares of Inari Medical at prices ranging from $80.87 to $81.36.

President And CEO Of Inari Medical Makes $2.4M Sale

Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.

Reasons to Hold on to Inari Medical (NARI) Stock For Now

Inari Medical, Inc. (NASDAQ: NARI) announced it has added Dana G. Mead, Jr. to its board of directors.

News for Inari Medical Stock (NARI)